Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix extension in Korean prostate cancer patients
NCT01215513Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2010
- Primary completion
- Apr 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started Sep 2010; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01215513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215513.